Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,350 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Abnormalities Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of HFCWO Vests on Spirometry Measurements

NCT03628456
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom Monarch
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis

NCT01686672
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Web Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 9 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance

NCT01113619
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28 or placebo
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 28, 2026, 10:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 28, 2026, 10:22 AM EDT
Terminated Not applicable Interventional

Airway Secretion Clearance in Cystic Fibrosis

NCT00839644
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
High frequency chest wall oscillation, Oscillatory Positive Expiratory Pressure, PD&P: Postural drainage and percussion
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 28, 2026, 10:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

AnovaOS Network Powered Patient Registry

NCT05013944
View directory record Official record
Conditions
Infectious Disease, Neoplasms, Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89), Endocrine, Nutritional and Metabolic Diseases (E00-E89), Mental and Behavioural Disorders, Diseases of the Nervous System, Diseases of the Eye and Adnexa, Diseases of the Ear and Mastoid Process, Diseases of the Circulatory System, Diseases of the Respiratory System, Diseases of the Digestive System, Diseases of the Skin and Subcutaneous Tissue, Diseases of the Musculoskeletal System and Connective Tissue, Diseases of the Genitourinary System, Pregnancy, Childbirth and the Puerperium, Certain Conditions Originating in the Perinatal Period, Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99), Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified, Injury, Poisoning and Certain Other Consequences of External Causes, External Causes of Morbidity and Mortality, Factors Influencing Health Status and Contact With Health Services
Interventions
Not listed
Lead sponsor
Anova Enterprises, Inc
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

NCT05360680
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Interventions
CUE-102
Drug
Lead sponsor
Cue Biopharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Recruiting Early Phase 1 Interventional

Personalized Theratyping Trial

NCT03587961
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Symdeko
Drug
Lead sponsor
George Solomon
Other
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

NCT02700087
View directory record Official record
Conditions
Laryngomalacia, Acid Reflux, Stridor
Interventions
ranitidine or famotidine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 4 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

NCT00128492
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

NCT00609505
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions
Telemedicine, Face-to-Face
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
4
States / cities
Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Cystic Fibrosis

NCT01379040
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Cystic Fibrosis patients
Other
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational

Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review

NCT01515631
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 28, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Enrolling by invitation No phase listed Observational

Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils

NCT07639853
View directory record Official record
Conditions
Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid, Pelvic Venous Disorders, Peripheral Aneurysms, Portal Vein Embolization, Type II Endoleak, Varicocele, Hemorrhage
Interventions
Concerto Versa™ Detachable Coils
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Piscataway, New Jersey • New York, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

NCT01054339
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
rAAV1-CB-hAAT
Drug
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

NCT05856331
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537, Zemaira
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT04172441
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
7 Days to 364 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Effects of a Partially Supervised Conditioning Program in CF

NCT01744561
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Wuerzburg University Hospital
Other
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 28, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782
View directory record Official record
Conditions
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
Interventions
ECUR-506
Genetic
Lead sponsor
iECURE, Inc.
Industry
Eligibility
24 Hours to 7 Months · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Terminated Not applicable Interventional

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

NCT01983774
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 28, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 28, 2026, 10:22 AM EDT